CELLECTIS(EPA:ALCLS) stock Fundamental Analysis

Fundamental Rating

We assign a fundamental rating of 3 out of 10 to ALCLS. ALCLS was compared to 71 industry peers in the Biotechnology industry. While ALCLS seems to be doing ok healthwise, there are quite some concerns on its profitability. ALCLS is quite expensive at the moment. It does show a decent growth rate.

Quickly go to:

1. Profitability

1.1 Basic Checks

ALCLS had negative earnings in the past year.

In the past year ALCLS had a positive cash flow from operations.

In the past 5 years ALCLS always reported negative net income.

ALCLS had negative operating cash flow in 4 of the past 5 years.

1.2 Ratios

ALCLS has a better Return On Assets (-14.12%) than 67.61% of its industry peers.

Looking at the Return On Equity, with a value of -41.34%, ALCLS is in line with its industry, outperforming 56.34% of the companies in the same industry.

		Industry Rank	Sector Rank
ROA	-14.12%
ROE	-41.34%
ROIC	N/A

ROA(3y)-26.82%

ROA(5y)-25.52%

ROE(3y)-79.12%

ROE(5y)-63.67%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

ALCLS has a Gross Margin (4.64%) which is comparable to the rest of the industry.

ALCLS does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	4.64%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

ALCLS does not have a ROIC to compare to the WACC, probably because it is not profitable.

ALCLS has more shares outstanding than it did 1 year ago.

The number of shares outstanding for ALCLS has been increased compared to 5 years ago.

The debt/assets ratio for ALCLS has been reduced compared to a year ago.

2.2 Solvency

ALCLS has an Altman-Z score of -1.05. This is a bad value and indicates that ALCLS is not financially healthy and even has some risk of bankruptcy.

ALCLS has a Altman-Z score (-1.05) which is comparable to the rest of the industry.

The Debt to FCF ratio of ALCLS is 4.88, which is a neutral value as it means it would take ALCLS, 4.88 years of fcf income to pay off all of its debts.

ALCLS has a Debt to FCF ratio of 4.88. This is amongst the best in the industry. ALCLS outperforms 90.14% of its industry peers.

ALCLS has a Debt/Equity ratio of 0.65. This is a neutral value indicating ALCLS is somewhat dependend on debt financing.

ALCLS's Debt to Equity ratio of 0.65 is in line compared to the rest of the industry. ALCLS outperforms 47.89% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	0.65
Debt/FCF	4.88
Altman-Z	-1.05

ROIC/WACCN/A

WACC6.22%

2.3 Liquidity

ALCLS has a Current Ratio of 1.73. This is a normal value and indicates that ALCLS is financially healthy and should not expect problems in meeting its short term obligations.

The Current ratio of ALCLS (1.73) is comparable to the rest of the industry.

ALCLS has a Quick Ratio of 1.73. This is a normal value and indicates that ALCLS is financially healthy and should not expect problems in meeting its short term obligations.

ALCLS has a Quick ratio of 1.73. This is comparable to the rest of the industry: ALCLS outperforms 43.66% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	1.73
Quick Ratio	1.73

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

ALCLS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 80.34%, which is quite impressive.

Looking at the last year, ALCLS shows a very strong growth in Revenue. The Revenue has grown by 412.40%.

Measured over the past years, ALCLS shows a quite strong growth in Revenue. The Revenue has been growing by 16.44% on average per year.

EPS 1Y (TTM)80.34%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%111.43%

Revenue 1Y (TTM)412.4%

Revenue growth 3Y8.44%

Revenue growth 5Y16.44%

Sales Q2Q%662.06%

3.2 Future

Based on estimates for the next years, ALCLS will show a very negative growth in Earnings Per Share. The EPS will decrease by -75.28% on average per year.

ALCLS is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 30.02% yearly.

EPS Next Y-235.09%

EPS Next 2Y-58.04%

EPS Next 3Y-75.28%

EPS Next 5YN/A

Revenue Next Year11.14%

Revenue Next 2Y-24.22%

Revenue Next 3Y24.63%

Revenue Next 5Y30.02%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

ALCLS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ALCLS. No positive earnings are expected for the next year.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

ALCLS's Price/Free Cash Flow ratio is rather cheap when compared to the industry. ALCLS is cheaper than 94.37% of the companies in the same industry.

		Industry Rank	Sector Rank
P/FCF	8.22
EV/EBITDA	N/A

4.3 Compensation for Growth

A cheap valuation may be justified as ALCLS's earnings are expected to decrease with -75.28% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y-58.04%

EPS Next 3Y-75.28%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

ALCLS does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

CELLECTIS

EPA:ALCLS (4/25/2025, 7:00:00 PM)

1.38

-0.01 (-0.43%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)03-13 2025-03-13/amc

Earnings (Next)05-07 2025-05-07

Inst Owners20.91%

Inst Owner ChangeN/A

Ins Owners3.88%

Ins Owner ChangeN/A

Market Cap138.40M

Analysts86.15

Price Target5.1 (269.57%)

Short Float %N/A

Short RatioN/A

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)2

Avg EPS beat(2)82%

Min EPS beat(2)18.3%

Max EPS beat(2)145.69%

EPS beat(4)4

Avg EPS beat(4)73.41%

Min EPS beat(4)6.42%

Max EPS beat(4)145.69%

EPS beat(8)6

Avg EPS beat(8)27.22%

EPS beat(12)9

Avg EPS beat(12)23.55%

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)2

Avg Revenue beat(2)108.7%

Min Revenue beat(2)55.84%

Max Revenue beat(2)161.56%

Revenue beat(4)4

Avg Revenue beat(4)91.56%

Min Revenue beat(4)50.31%

Max Revenue beat(4)161.56%

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)0%

PT rev (3m)0%

EPS NQ rev (1m)8.04%

EPS NQ rev (3m)8.04%

EPS NY rev (1m)-18.27%

EPS NY rev (3m)1.84%

Revenue NQ rev (1m)19.78%

Revenue NQ rev (3m)19.78%

Revenue NY rev (1m)0%

Revenue NY rev (3m)0%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	2.13
P/FCF	8.22
P/OCF	6.85
P/B	1.2
P/tB	1.21
EV/EBITDA	N/A

EPS(TTM)-0.31

EYN/A

EPS(NY)-1.03

Fwd EYN/A

FCF(TTM)0.17

FCFY12.16%

OCF(TTM)0.2

OCFY14.6%

SpS0.65

BVpS1.15

TBVpS1.14

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-14.12%
ROE	-41.34%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	4.64%
FCFM	25.96%

ROA(3y)-26.82%

ROA(5y)-25.52%

ROE(3y)-79.12%

ROE(5y)-63.67%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score7

Asset Turnover0.19

Health

		Industry Rank	Sector Rank
Debt/Equity	0.65
Debt/FCF	4.88
Debt/EBITDA	N/A
Cap/Depr	19.36%
Cap/Sales	5.21%
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	1.73
Quick Ratio	1.73
Altman-Z	-1.05

F-Score7

WACC6.22%

ROIC/WACCN/A

Cap/Depr(3y)12.8%

Cap/Depr(5y)139.39%

Cap/Sales(3y)9.66%

Cap/Sales(5y)33.81%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)80.34%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%111.43%

EPS Next Y-235.09%

EPS Next 2Y-58.04%

EPS Next 3Y-75.28%

EPS Next 5YN/A

Revenue 1Y (TTM)412.4%

Revenue growth 3Y8.44%

Revenue growth 5Y16.44%

Sales Q2Q%662.06%

Revenue Next Year11.14%

Revenue Next 2Y-24.22%

Revenue Next 3Y24.63%

Revenue Next 5Y30.02%

EBIT growth 1Y35.21%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year-14.35%

EBIT Next 3YN/A

EBIT Next 5Y-29.24%

FCF growth 1Y174.16%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y192.9%

OCF growth 3YN/A

OCF growth 5YN/A

CELLECTIS (ALCLS.PA) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens